Methods for Using Aggregate Historical Control Data in Meta-Analyses of Clinical Trials With Time-to-Event Endpoints

被引:5
|
作者
Holzhauer, Bjorn [1 ]
机构
[1] Novartis Pharma AG, Biostat Sci & Pharmacometr, Basel, Switzerland
来源
关键词
Bayesian model averaging; Rare events; Robust meta-analytic predictive prior; Safety meta-analysis; Shrinkage priors; ANALYTIC-PREDICTIVE PRIORS; INFORMATION;
D O I
10.1080/19466315.2019.1610043
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
This article deals with comparing a test with a control therapy using meta-analyses of data from randomized controlled trials with a time-to-event endpoint. Such analyses can often benefit from prior information about the distribution of control group outcomes. One possible source of this information is the published aggregate data about control groups of historical trials from the medical literature. We review methods for making posterior inference about exponentially distributed event times more robust to prior-data conflicts by discounting the prior information based on the extent of observed prior-data conflict. We use simulations to compare analyses without prior information with the meta-analytic combined, meta-analytic predictive and robust meta-analytic predictive approaches, as well as Bayesian model averaging using shrinkage priors. Bayesian model averaging via shrinkage priors with well-chosen hyperpriors performed best in terms of credible interval coverage and mean-squared error across scenarios. For the robust meta-analytic predictive approach, there was little benefit in increasing the weight of the informative mixture components beyond 0.2-0.5. This was the case even when little prior-data conflict was expected, except with very sparse data or substantial between-trial heterogeneity in control group hazard rates. for this article are available online.
引用
收藏
页码:107 / 116
页数:10
相关论文
共 50 条
  • [31] Hazard ratio inference in stratified clinical trials with time-to-event endpoints and limited sample size
    Xu, Rengyi
    Mehrotra, Devan V.
    Shaw, Pamela A.
    PHARMACEUTICAL STATISTICS, 2019, 18 (03) : 366 - 376
  • [32] Doubly adaptive biased coin design to improve Bayesian clinical trials with time-to-event endpoints
    Cao, Wenhao
    Zhu, Hongjian
    Wang, Li
    Zhang, Lixin
    Yu, Jun
    STATISTICS IN MEDICINE, 2024, 43 (09) : 1743 - 1758
  • [33] A guide on meta-analysis of time-to-event outcomes using aggregate data in vascular and endovascular surgery
    Antoniou, George A.
    Antoniou, Stavros A.
    Smith, Catrin Tudur
    JOURNAL OF VASCULAR SURGERY, 2020, 71 (03) : 1002 - 1005
  • [34] AN OVERVIEW OF STATISTICAL METHODS FOR META-ANALYSES COMBINING INDIVIDUAL PARTICIPANT DATA AND AGGREGATE DATA
    Ellis, A. G.
    Dahabreh, I
    Wong, J. B.
    Trikalinos, T. A.
    VALUE IN HEALTH, 2016, 19 (03) : A91 - A91
  • [35] Network Meta-Analysis of Time-to-Event Endpoints With Individual Participant Data Using Restricted Mean Survival Time Regression
    Hua, Kaiyuan
    Wang, Xiaofei
    Hong, Hwanhee
    BIOMETRICAL JOURNAL, 2025, 67 (01)
  • [36] Guidelines for the definitions of time-to-event endpoints in randomized clinical trials: Results of the DATECAN Project for Sarcomas and GISTs
    Bellera, Carine A.
    Ouali, Monia
    Penel, Nicolas
    Bonvalot, Sylvie
    Casali, Paolo Giovanni
    Delannes, Martine
    Nielsen, Ole Steen
    Mathoulin-Pelissier, Simone
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [37] Guidelines for time-to-event endpoints in gastrointestinal cancer using real-world data
    Vissers, P.
    Elferink, M. A. G.
    Bonsing, B.
    Vandergeest, L.
    Koopman, M.
    van Laarhoven, H. W. M.
    Nieuwenhuijzen, G.
    van Rossum, P. S. N.
    Sijtsma, F. P. C.
    Vink, G. R.
    de vos-Geelen, J.
    Wilmink, H.
    Dewilt, H.
    Verhoeven, R. H. A.
    van Erning, F. N.
    ANNALS OF ONCOLOGY, 2024, 35 : S207 - S207
  • [38] Guidelines for the definitions of time-to-event endpoints in randomized clinical trials: Results of the datecan project for breast group
    Gourgou-Bourgade, S.
    Dabakuyo-Yonli, S.
    Cameron, D.
    Cardoso, F.
    Poortmans, P.
    Asselain, B.
    Azria, D.
    CANCER RESEARCH, 2013, 73
  • [39] Guidelines for the definitions of time-to-event endpoints in randomized clinical trials: Results of the DATECAN Project for Breast Group
    Gourgou, Sophie
    Dabakuyo, Tienhan Sandrine
    Asselain, Bernard
    Azria, David
    Cameron, David A.
    Cardoso, Fatima
    Poortmans, Philip M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [40] Dynamic path analysis for exploring treatment effect mediation processes in clinical trials with time-to-event endpoints
    Kormaksson, Matthias
    Lange, Markus Reiner
    Demanse, David
    Strohmaier, Susanne
    Duan, Jiawei
    Xie, Qing
    Carbini, Mariana
    Bossen, Claudia
    Guettner, Achim
    Maniero, Antonella
    STATISTICS IN MEDICINE, 2024, 43 (23) : 4614 - 4634